Ebola patient Dr. Rick Sacra received treatment with Tekmira Pharmaceuticals' experimental ebola therapy TKM-Ebola for seven days, Nebraska Medical Center confirmed.
Gilead's goal is to create new versions of its blockbuster HIV combination therapies, replacing Viread with TAF.
The buyers of Northwest's debt want the stock price to decline before Feb. 15, 2015, because a lower stock price also will drop the conversion price of the notes.
Activist investor Alex Denner is gaining an ally on Ariad's Board.
On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
Avanir Pharmaceuticals are surging Monday after demonstrating once again that cough syrup produces a nice, mellow high
NPS Pharmaceuticals shares are weak Monday following a rough outing for its hormone replacement therapy Natpara at an FDA advisory panel on Friday.
Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.